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Objectives:
To evaluate cystatin-C, a novel measure of renal function, as a predictor of mortality in elderly persons with heart failure (HF), and to compare it with creatinine.
Background:
Renal function is an important prognostic factor in patients with HF, but creatinine levels, which in part reflect muscle mass, may be insensitive for detecting renal insufficiency.
Methods:
279 Cardiovascular Health Study participants with prevalent HF and measures of serum cystatin-C and creatinine were followed for mortality outcomes over a median of 6.5 years.
Results:
Median creatinine and cystatin-C levels were 1.05mg/dL and 1.26mg/L. Each SD increase in cystatin-C (0.35mg/L) was associated with a 31% greater adjusted mortality risk (95% CI: 20-43%; p<0.001); whereas each SD increase in creatinine (0.39mg/dL) was associated with a 17% greater adjusted mortality risk (95% CI: 1-36%; p=0.04). When both measures were combined in a single adjusted model, cystatin-C remained associated with elevated mortality risk (1.60; 1.32-1.94), whereas creatinine levels appeared associated with lower risk (0.73; 0.57-0.95).
Conclusions:
Cystatin-C is a stronger predictor of mortality than creatinine in elderly persons with HF.
If confirmed in future study, this new marker of renal function could improve risk stratification in patients with HF.
Cystatin-C and mortality in heart failure Condensed Abstract Cystatin-C, a novel measure of renal function, was evaluated as a predictor of mortality in elderly persons with heart failure (HF). 279 Cardiovascular Health Study participants with prevalent HF were followed for mortality outcomes. Each SD increase in cystatin-C (0.35mg/L) was associated with a 31% greater adjusted mortality risk (95% CI: 20-43%; p<0.001); whereas each SD increase in creatinine (0.39mg/dL) was associated with a 17% greater adjusted mortality risk (95% CI: 1-36%; p=0.04). Cystatin-C appears to be a stronger predictor of mortality than creatinine in elderly persons with HF. Renal dysfunction is an important adverse prognostic factor in patients with heart failure (HF) (1-3). However, the standard clinical measures of renal function, serum creatinine and creatinine-based estimates of glomerular filtration rate (GFR), may be less correlated with actual GFR in the elderly (4) . Cystatin-C, a novel serum measure of renal function (5) , is a serine protease inhibitor that is released from all functioning cells. Although studies suggest that cystatin-C may better approximate GFR than creatinine (5-7), their associations with HF outcomes have not been compared. In this pilot study, we compared cystatin-C with creatinine and estimated GFR as mortality predictors in a cohort of elderly patients with HF.
METHODS

Participants
The Cardiovascular Heath Study (CHS) is a community-based, longitudinal study of adults aged >65 years at entry. The objective of the study was to evaluate risk factors for the development and progression of cardiovascular disease (8) An expert panel adjudicated diagnoses of HF based on published criteria (9, 10) . The study design was approved by the Institutional Review Board at the University of Washington.
Predictors
Renal function:
Cystatin-C was measured from samples collected at the 1992-1993 visit and stored at -70°C, using a BNII nephelometer (Dade Behring Inc., Deerfield, IL) and a particle enhanced immunonepholometric assay (N Latex Cystatin-C) (11).
Serum creatinine was measured using the Kodak Ektachem 700 Analyzer (Eastman Kodak, Rochester, New York), a colorimetric method. We used the simplified MDRD equation to estimate GFR from serum creatinine. 
Analysis
We compared participants with HF who survived to those who died during follow-up. To evaluate measures of renal function as predictors of mortality, cystatin-C and creatinine were evaluated as continuous variables per standard deviation. We used multivariate Cox proportional hazards models that were adjusted for all the above characteristics as candidate predictors.
Covariates, whose entry into the model changed the coefficient of cystatin-C by 5% were retained and included in the final models for cystatin-C, creatinine, and estimated GFR. We also evaluated models that included both cystatin-C and creatinin e. We did not evaluate estimated GFR as a continuous variable because of the implications of modeling ratios in regression analyses -in particular, problems with spurious correlations and the loss of scientific interpretation of the coefficient by adjusting for GFR (12) .
We evaluated the association of quartiles of estimated GFR, cystatin-C, and creatinine as predictors of mortality. Creatinine quartiles were sex-specific to insure adequate representation of men and women within each. We determined the unadjusted and multivariate-adjusted risk for quartiles 2-4 compared with quartile 1. Multivariate analyses were done using the covariates selected for continuous variable analyses.
We compared adjusted mortality risk of participants with cystatin-C levels above and below the median after stratifying the cohort by the median creatinine and estimated GFR levels.
S-Plus (release 6.1, Insightful Inc, Seattle, WA) and SPSS statistical software (release 12.0.0, SPSS Inc, Chicago, IL) were used for the analyses.
RESULTS
During a median (range) follow-up time of 6.5 years (0.1-9.1), 182 (65%) died and the annual mortality risk was 11.1%. Characteristics associated with mortality include advanced age, male sex, reduced body mass index, and prior stroke ( Table 1) .
Mean cystatin-C and creatinine levels were significantly higher and estimated GFR was lower among the participants who died during follow-up.
A one SD change in cystatin-C (0.34mg/L) was associated with mortality risk in After multivariate adjustment, the highest quartile of cystatin-C (>1.55mg/L) was associated with a two-fold mortality risk, whereas the lower three quartiles had similar risk ( Table 2) . Although the highest quartile of creatinine had elevated mortality risk in unadjusted analysis, this association was not significant in adjusted analysis. After multivariate adjustment, the highest quartile of estimated GFR was associated with a 60% greater mortality risk than the lowest quartile (Table 2) .
We evaluated the association of cystatin-C levels above and below the median (1.26mg/L) with mortality after stratifying by the median creatinine (1.05mg/dL) and estimated GFR levels (61ml/min/1.73m 2 ) (Figure 1) . Participants with cystatin-C levels above the median were at similarly elevated mortality risk, regardless of whether their creatinine or estimated GFR levels were above or below the median.
DISCUSSION
Cystatin-C was an independent predictor of mortality in elderly persons with HF. Persons with cystatin-C levels in the highest quartile (>1.55mg/L) had a two-fold adjusted mortality risk compared with those in the lowest quartile. Although creatinine levels were associated with mortality in a linear model, the association of cystatin-C with mortality was greater in magnitude, and persisted even after adjustment for creatinine. This novel measure of renal function could potentially improve the risk stratification of elderly patients with HF.
Prior studies have found that renal dysfunction, measured by creatinine or estimated GFR, is a strong predictor of mortality in the setting of HF (1-3). Because creatinine levels are influenced heavily by muscle mass, estimated GFR is recommended by the National Kidney Foundation as the appropriate renal function measure for clinicians (13) . However, estimates of GFR may not be optimal in persons with normal creatinine levels (14) . Cystatin-C may overcome some of the limitations of creatinine and estimated GFR, as it does not appear to be dependent on age, sex, or body mass.
This study has certain important limitations. The small sample size of participants with HF limited power to detect differences across the lower quartiles of each renal function measure, or to conduct subgroup analyses by sex and race. This is a sample of elderly subjects with heart failure, so we do not know whether cystatin-C would have advantages over creatinine in younger patients or those with different diagnoses. In addition, though we presume that the association of cystatin-C with mortality is caused by its correlation with GFR, we cannot exclude the possibility that circulating cystatin-C levels have either directly harmful effects or reflect another pathological process distinct from renal function.
CONCLUSION
Independent of both creatinine and traditional risk factors, cystatin-C is a strong predictor of mortality in persons with HF. Further study will be needed to confirm this finding and to determine whether measurement of cystatin-C would have clinical benefits in the care of elderly patients with HF.
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